EFFICACY OF COMBINATION OF TIOTROPIUM/OLODATEROL IN PATIENTS WITH COPD IN REAL CLINICAL PRACTICE

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Medicine

Background:

• Chronic obstructive pulmonary disease (COPD) management requires effective long-term therapies.
• Real-world data is crucial for understanding treatment efficacy beyond clinical trials.
• Tiotropium/olodaterol is a combination inhaler for COPD symptom relief.

Purpose of the Study:

• To evaluate the real-world effectiveness of the tiotropium/olodaterol combination in COPD patients.
• To assess the impact of this therapy on exacerbation rates, medication usage, and symptom scores.

Main Methods:

• A prospective study included 100 COPD patients (mean age 64.09 years, 66% male).
• Data on exacerbations, antibiotic, glucocorticosteroid, and methylxanthine use were collected at baseline and 1-year follow-up.
• Modified Medical Research Council (mMRC) and COPD Assessment Test (CAT) scores were assessed at baseline, 4-6 weeks, and 1 year.

Main Results:

• Tiotropium/olodaterol significantly reduced COPD exacerbations (from 2.63 to 1.63) and hospital admissions (from 1.2 to 0.37).
• Associated reductions in antibiotic use (courses and duration) and glucocorticosteroid use were observed.
• Significant improvements in mMRC scores (2.3 to 1.87) and CAT scores (23.28 to 15.77) were noted.

Conclusions:

• The tiotropium/olodaterol combination demonstrated significant efficacy in managing COPD in a real-world clinical setting.
• Therapy led to a marked decrease in exacerbations and reduced reliance on rescue medications like antibiotics and corticosteroids.
• Improved symptom burden, as indicated by mMRC and CAT scores, further supports the benefits of this combination therapy.